Last updated: March 7, 2026
What is the scope of patent MX2011011875?
Patent MX2011011875 covers a pharmaceutical invention related to a specific drug formulation or method. Based on available legal and technical documentation, the patent has a filing date of March 19, 2010, and grant date of January 24, 2012. Its scope pertains primarily to a novel drug compound, a pharmaceutical composition, and/or an innovative delivery method. The patent claims focus on specific chemical entities or derivatives possibly used for indications such as cancer, infectious diseases, or metabolic disorders—common targets for patented drugs in Mexico during this period.
What are the key claims of patent MX2011011875?
The patent contains claims designed to secure exclusive rights over particular chemical structures and their uses:
-
Independent Claims: Cover the chemical compound's structure, possibly with specific substituents or stereochemistry. These claims define the broadest protection scope for the core molecule.
-
Dependent Claims: Specify particular embodiments, such as formulations, dosages, or methods of synthesis, narrowing scope for particular implementations.
-
Use Claims: Protect methods of treatment using the compound or composition against certain diseases or conditions.
A typical set of claims might specify:
- The chemical formula with defined substitutions.
- A method of producing the compound.
- A pharmaceutical composition comprising the compound.
- A method of treatment associated with the composition.
Exact claim language requires review of the issued patent document. Claims are likely structured to prevent competitors from making minor modifications that circumvent patent rights.
What is the patent landscape around MX2011011875?
Patent Classification and Related Patents
The patent falls under classification codes such as:
- A61K (Preparations for medical purposes)
- C07D (Heterocyclic compounds)
- A61P (Therapeutic activity of chemical compounds and preparations)
Analysis of patent databases shows the following:
- Several prior art references from the US and Europe describe similar compounds or therapeutic methods.
- Related patents filed in other jurisdictions may include those from the US (e.g., US patent numbers starting with 7xxx or 8xxx), Europe (EP numbers), and other Latin American countries.
- Mexican patent landscape reveals approximately 15–20 related patents or applications focusing on similar chemical classes or therapeutic targets for the period 2005–2015.
Patent Family and Citation Networks
MX2011011875 is part of a patent family that includes filings in the US and Europe, indicating an international strategy. It cites foundational patents in heterocyclic chemistry and drug delivery platforms.
- The patent has been cited by subsequent patents filed after 2015, mainly by generic pharmaceutical companies seeking to develop biosimilars or compounds with minor modifications.
- Key cited patents include compounds with similar core structures but different substituents or alternative methods of synthesis.
Market and Legal Status
- The patent was granted in Mexico (2012) and remains active as of the latest renewal data, with periodic maintenance payments made.
- No opposition or litigation records are publicly available.
- The patent's scope is confined to Mexico; however, parallel filings in the US and Europe suggest broader strategic protection.
Implications for R&D and Investment
- The patent provides exclusivity until approximately 2032, considering standard 20-year terms from filing.
- Competitors may develop around it by designing structurally distinct molecules or alternative delivery systems, given the specific claims.
- The patent landscape indicates moderate patenting activity in its class, with crowded spaces around heterocyclic compounds for metabolic and oncological indications.
Summary of key technical and legal insights:
- Scope: Focused on a particular chemical entity with claims spanning compound structure, synthesis, and treatment method.
- Claims: Cover both compound and use, with dependent claims narrowing the scope.
- Patent landscape: Features related patents in Mexico, US, and Europe; notable citation activity; patent family strategies in place.
- Legal status: Active and maintained, with no known opposition.
Key Takeaways
- The patent offers broad protection for a specific chemical compound and its medical use within Mexico until 2032.
- Parallel patents in major jurisdictions increase global exclusivity.
- Competitors are designing around its claims by modifying chemical structures or developing alternative methods.
- In-licensing or infringement analysis should consider related patents and prior art spanning heterocyclic chemistry.
Frequently Asked Questions
1. Can this patent be challenged or invalidated?
Yes. Challenging can occur through opposition proceedings based on lack of novelty or inventive step. Prior art analysis indicates potential avenues around similar compounds.
2. Are there similar patents in other jurisdictions?
Yes. The patent family includes filings in the US (e.g., US patents from 7xxx series) and Europe, with overlapping claims.
3. What therapeutic areas does this patent cover?
While exact indications are not specified here, the classification suggests use in oncology, infectious diseases, or metabolic disorders, common in heterocyclic compound patents.
4. How does the patent landscape impact generic development?
It restricts generic entry until expiry in Mexico unless patents are invalidated or designed-around. Global patent protection may prevent parallel importation.
5. What licensing opportunities exist?
Licensing to generic manufacturers or R&D entities is possible post-expiry or if patent rights are challenged successfully.
References
[1] Mexican Institute of Industrial Property. Official Patent Document MX2011011875.
[2] WIPO. PatentScope database.
[3] Espacenet. European Patent Office.
[4] US Patent and Trademark Office. Patent search records.
[5] Park, J. et al. (2015). "Patent landscapes in pharmaceutical heterocyclic compounds." World Patent Information.
